Fabry disease: Identification of 50 novel α-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations
Tóm tắt
Fabry disease, an X-linked recessive inborn error of glycosphingolipid catabolism, results from the deficient activity of the lysosomal exoglycohydrolase, α-galactosidase A (EC 3.2.1.22; α-Gal A). The molecular lesions in the α-Gal A gene causing the classic phenotype of Fabry disease in 66 unrelated families were determined. In 49 families, 50 new mutations were identified, including: 29 missense mutations (N34K, T41I, D93V, R112S, L166G, G171D, M187T, S201Y, S201F, D234E, W236R, D264Y, M267R, V269M, G271S, G271V, S276G, Q283P, A285P, A285D, M290I, P293T, Q312H, Q321R, G328V, E338K, A348P, E358A, Q386P); nine nonsense mutations (C56X, E79X, K127X, Y151X, Y173X, L177X, W262X, Q306X, E338X); five splicing defects (IVS4-1G > A, IVS5-2A > G, IVS5 + 3A > G, IVS5 + 4A > G, IVS6-1G > C); four small deletions (18delA, 457delGAC, 567delG, 1096delACCAT); one small insertion (996insC); one 3.1 kilobase Alu-Alu deletion (which included exon 2); and one complex mutation (K374R, 1124delGAG). In 18 families, 17 previously reported mutations were identified, with R112C occurring in two families. In two classically affected families, affected males were identified with two mutations: one with two novel mutations, D264Y and V269M and the other with one novel (Q312H) and one previously reported (A143T) mutation. Transient expression of the individual mutations revealed that D264Y and Q312H were localised in the endoplasmic reticulum and had no detectable or markedly reduced activity, whereas V269M and A143T were localised in lysosomes and had approximately 10 per cent and approximately 35 per cent of expressed wild-type activity, respectively. Structural analyses based on the enzyme's three-dimensional structure predicted the effect of the 29 novel missense mutations on the mutant glycoprotein's structure. Of note, three novel mutations (approximately 10 per cent) were predicted not to significantly alter the glycoprotein's structure; however, they were disease causing. These studies further define the molecular heterogeneity of the α-Gal A mutations in classical Fabry disease, permit precise heterozygote detection and prenatal diagnosis, and provide insights into the structural alterations of the mutant enzymes that cause the classic phenotype.
Tài liệu tham khảo
Desnick RJ, Ioannou YA, Eng CM, et al: α-Galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease. Edited by: Scriver CR, Beaudet AL, Sly WS, et al. 2001, McGraw-Hill, New York, NY, 3733-3774. 8
Elleder M, Bradova V, Smid F, et al: Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol. 1990, 417: 449-455. 10.1007/BF01606034.
Nakao S, Kodama C, Takenaka T, et al: Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int. 2003, 64: 801-807. 10.1046/j.1523-1755.2003.00160.x.
Nakao S, Takenaka T, Maeda M, et al: An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995, 333: 288-293. 10.1056/NEJM199508033330504.
von Scheidt W, Eng CM, Fitzmaurice TF, et al: An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med. 1991, 324: 395-399. 10.1056/NEJM199102073240607.
Ashley GA, Shabbeer J, Yasuda M, et al: Fabry disease: Twenty novel α-galactosidase A mutations causing the classical phenotype. J Hum Genet. 2001, 46: 192-196. 10.1007/s100380170088.
Shabbeer J, Yasuda M, Luca E, Desnick RJ: Fabry disease: 45 novel mutations in the a-galactosidase. A gene causing the classical phenotype. Mol Genet Metab. 2002, 76: 23-30. 10.1016/S1096-7192(02)00012-4.
Barker DF, Schafer M, White R: Restriction sites containing CpG show a higher frequency of polymorphism in human DNA. Cell. 1984, 36: 131-138. 10.1016/0092-8674(84)90081-3.
Cooper C, Youssoufian H: The CpG dinucleotide and human genetic disease. Hum Genet. 1988, 78: 151-155. 10.1007/BF00278187.
Davies JP, Winchester BG, Malcolm S: Sequence variations in the first exon of alpha-galactosidase A. J Med Genet. 1993, 30: 658-663. 10.1136/jmg.30.8.658.
Fitzmaurice TF, Desnick RJ, Bishop DF: Human α-galactosidase A: High plasma activity expressed by the-30G → A allele. J Inherit Metab Dis. 1997, 20: 643-657. 10.1023/A:1005366224351.
Froissart R, Guffon N, Vanier MT, et al: Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab. 2003, 80: 307-314. 10.1016/S1096-7192(03)00136-7.
Yasuda M, Shabbeer J, Benson SD, et al: Fabry disease: Characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat. 2003, 22: 486-492. 10.1002/humu.10275.
Brown RM, Brown GK: X-chromosome inactivation and the diagnosis of X-linked disease in females. J Med Genet. 1993, 30: 177-184. 10.1136/jmg.30.3.177.
Lyon M: Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature. 1961, 190: 372-373. 10.1038/190372a0.
Willard HF: The sex chromosome and X chromosome inactivation. The Metabolic and Molecular Bases of Inherited Disease. Edited by: Scriver CR, Beaudet AL, Sly WS, et al. 2001, McGraw-Hill, New York, NY, 1191-1212.
Eng CM, Banikazemi M, Gordon R, et al: A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet. 2001, 68: 711-722. 10.1086/318809.
Eng CM, Guffon N, Wilcox WR, et al: Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Eng J Med. 2001, 345: 9-16. 10.1056/NEJM200107053450102.
Schiffmann R, Kopp JB, Austin HA, et al: Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA. 2001, 285: 2743-2749. 10.1001/jama.285.21.2743.
Wilcox WR, Banikazemi M, Guffon N, et al: Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004, 75: 65-74. 10.1086/422366.
Galanos J, Nicholls K, Grigg L, et al: Clinical features of Fabry's disease in Australian patients. Intern Med J. 2002, 32: 575-584. 10.1046/j.1445-5994.2002.00291.x.
MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001, 38: 769-775. 10.1136/jmg.38.11.769.
Desnick RJ, Brady R, Barranger J, et al: Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003, 138: 338-346.
Fan JQ: A contradictory treatment for lysosomal storage disorders: Inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci. 2003, 24: 355-360. 10.1016/S0165-6147(03)00158-5.
Asano N, Ishii S, Kizu H, et al: In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalacto-nojirimycin and its derivatives. Eur J Biochem. 2000, 267: 4179-4186. 10.1046/j.1432-1327.2000.01457.x.
Desnick RJ, Schuchman EH: Enzyme replacement and enhancement therapies: Lessons from lysosomal disorders. Nat Rev Genet. 2002, 3: 954-966. 10.1038/nrg963.
Fan JQ, Ishii S, Asano N, Suzuki Y: Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999, 5: 112-115. 10.1038/4801.
Ishii S, Yoshioka H, Mannen K, et al: Transgenic mouse expressing human mutant a-galactosidase A in an endogenous enzyme deficient background: A biochemical animal model for studying active-site specific chaperone therapy for Fabry disease. Biochim Biophys Acta. 2004, 1690: 250-257. 10.1016/j.bbadis.2004.07.001.
Frustaci A, Chimenti C, Ricci R, et al: Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Eng J Med. 2001, 345: 25-32. 10.1056/NEJM200107053450104.
Garman SC, Garboczi DN: The molecular defect leading to Fabry disease: Structure of human alpha-galactosidase. J Mol Biol. 2004, 337: 319-335. 10.1016/j.jmb.2004.01.035.
Matsuzawa F, Aikawa SI, Doi H, et al: Fabry disease: Correlation between structural changes in α-galactosidase, and clinical and biochemical phenotypes. Hum Genet. 2005, 117: 317-328. 10.1007/s00439-005-1300-5.
Desnick RJ, Allen KY, Desnick SJ, et al: Fabry's disease: Enzymatic diagnosis of hemizygotes and heterozygotes. α-Galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med. 1973, 81: 157-171.
Shabbeer J, Robinson M, Desnick RJ: Detection of α-galactosidase A mutations causing Fabry disease by denaturing high performance liquid chromatography. Hum Mutat. 2005, 25: 299-305. 10.1002/humu.20144.
Wang A, Bishop D, Desnick R: Human α-N-acetylgalactosaminidase: Molecular cloning, nucleotide sequence, and expression of a full-length cDNA. J Biol Chem. 1990, 265: 21859-21866.
Higgins ME, Davies JP, Chen FW, Ioannou YA: Niemann-Pick C1 is a late endosome-resident protein that transiently associates with lysosomes and the trans-Golgi network. Mol Genet Metab. 1999, 68: 1-13. 10.1006/mgme.1999.2882.
Garman SC, Hannick L, Zhu A, Garboczi DN: The 1.9 A structure of α-N-acetylgalactosaminidase: Molecular basis of glycosidase deficiency diseases. Structure (Camb). 2002, 10: 425-434. 10.1016/S0969-2126(02)00726-8.
Jones TA, Zou JY, Cowan SW, Kjeldgaard M: Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. 1991, A47: 110-119.
Brunger AT, Adams PD, Clore GM, et al: Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. 1998, D54: 905-921.